771P Correlation of gut microbiome composition with checkpoint inhibitor induced severe immune-related adverse events

Verheijden, Rik J.; Wijgert, J.J.H.H. van de; May, Anne M.; Viveen, Marco C.; Rogers, Malbert R. C.; Paganelli, Fernanda L.; Suijkerbuijk, K.P.M.

doi:10.1016/j.annonc.2022.07.897

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, patients with the highest Streptococcus abundance all developed irAEs, had significantly decreased PFS and often received proton pump inhibitor (PPI) therapy [42 ▪▪ ]. In a second prospective analysis of 110 patients treated with ICIs with valid baseline fecal samples, enrichment in Streptococcus was also described in patients developing severe grade at least 3 irAE [43].…”

Section: Bacterial Repertoire and Immune-related Adverse Eventsmentioning

confidence: 99%

Following your gut: the emerging role of the gut microbiota in predicting and treating immune-related adverse events

Desîlets

Elkrief

2023

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of reviewAlthough immune checkpoint inhibition has reshaped the therapeutic landscape leading to improved outcomes across an array of both solid and hematologic malignancies, a significant source of morbidity is caused by immune-related adverse events (irAEs) caused by these agents.Recent findingsThe gut microbiota has emerged as a biomarker of response to these agents, and more recently, also as a key determinant of development of irAEs. Emerging data have revealed that enrichment of certain bacterial genera is associated with an increased risk of irAEs, with the most robust evidence pointing to an intimate connection with the development of immune-related diarrhea and colitis. These bacteria include Bacteroides, Enterobacteriaceae, and Proteobacteria (such as Klebsiella and Proteus). Lachnospiraceae spp. and Streptococcus spp. have been implicated irAE-wide in the context of ipilimumab.SummaryWe review recent lines of evidence pointing to the role of baseline gut microbiota on the development of irAE, and the potentials for therapeutic manipulation of the gut microbiota in order to reduce irAE severity. The connections between gut microbiome signatures of response and toxicity will need to be untangled in further studies.

show abstract

Section: Bacterial Repertoire and Immune-related Adverse Eventsmentioning

confidence: 99%